Surprisingly, 22% recommended a molecular analysis (EGFR, ROS, ALK1 status) in unresectable LA-NSCLC, in which platinum-based chemotherapy and radiotherapy represent the standard of care [12]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.